FDA reviews DNA-based colon cancer screening kits

The Food and Drug Administration is weighing the benefits and risks of two experimental colon cancer screening tests which use DNA from a patient's stool to detect dangerous tumors and growths.

FDA scientists have questions about the accuracy and the real-world impact of the kits, if they are approved. The agency posted its reviews of the tests from Epigenomics and Exact Sciences online, ahead of a two-day meeting that starts Wednesday.

Doctors have long used stool tests to look for hidden blood that can be a warning sign of tumors and .

Both tests reviewed by the FDA were more accurate at detecting tumors and worrisome growths than the traditional blood stool test. However, both tests also returned more false positives—reporting growths when none were actually present.

4 /5 (2 votes)
add to favorites email to friend print save as pdf

Related Stories

Study: Colonoscopy cuts colon cancer death risk

Feb 22, 2012

(AP) -- Millions of people have endured a colonoscopy, believing the dreaded exam may help keep them from dying of colon cancer. For the first time, a major study offers clear evidence that it does.

Recommended for you

70-gene signature not cost-effective in breast cancer

Oct 18, 2014

(HealthDay)—For patients with node-negative breast cancer (NNBC), the 70-gene signature is unlikely to be cost-effective for guiding adjuvant chemotherapy decision making, according to a study published ...

User comments